Randomized trial of high-dose pyridoxine in combination with standard hormonal therapy in West syndrome

West Syndrome (WS) is a distinct, age-dependent, developmental and epileptic encephalopathy of infancy with poor neurodevelopmental outcome. The first-line therapeutic options are hormonal therapy (adrenocorticotropic hormone [ACTH] or oral steroids), vigabatrin or a combination of the two as suggested by the high quality of clinical evidence [1,2]. The short-term efficacy of hormonal therapy to eliminate epileptic spasms is variable among studies ranging from 37% to 73% [3,4]. Hormonal therapy has also been observed to be superior to vigabatrin therapy (76% versus 54%) [5].

Source: Seizure: European Journal of Epilepsy - May 28, 2021 Category: Neurology Authors: Arundhati Banerjee, Jitendra Kumar Sahu, Naveen Sankhyan, Smita Pattanaik, Renu Suthar, Arushi Gahlot Saini, Lokesh Saini, Sandeep Negi, Prahbhjot Malhi, Pratibha Singhi Source Type: research